In 1992 an annual Simian herpes B virus (BV) screening program me for an experimental group of macaque monkeys (Ma c a c a m ula tta and Ma ca c a fa sc icula ris ) was initiat ed with the aim of establ ishing a speci®c pathogen free (SPF) colony. In June 1999 one animal was found to be unexpectedly BV positive (non-negative ). T he investigat ion of this result highlights some of the issues and dif®culties that may be encountered in such a programme.
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Cercopithicine He rpe svi rus type 1, also called He rpe svirus sim ia e or Simian herpes B virus, or most commonly BV, belongs to the simplex sub-fam ily of the alphaherpesviruses. Virological and serological evidence demonstrates that members of this subfam ily are indigenous throughout the primat e species. BV infects the asiati c macaque species, Simian Agent 8 (SA8) infects the vervet monkey species, He rpe svi rus pa pio type 2 (HVP2) infects baboons, and He rpe sviru s ta m a rinus infects squirrel monkeys. T hese viruses are in the same sub-group as human herpes simplex virus (HSV). Correspondingly there are extensive cross reactive antibody responses between the viruses. T here is serological evidence for simplex type viruses in a wide range of Old and New World primate species (Eberle & Hilliard 1995 ) .
Typically, in the natural host, simplex like viruses cause a mild or inapparent disease. Infection is lifelong with viruses adopting a latent state in sensory ganglia with periodic reactivation as a result of physiological or immunological stress (Chellman e t a l. 1992 ) . BV is an indigenous infection of primates of the genus Ma c a c a in Asia, although most of the studies undertaken have been restricted to either rhesus (M. m ula tta ) or cynomolgus (M. fa sc ic ula ris ) species. Clinical signs in monkeys parallel HSV in man; in rhesus, primary infection in young anim als is usually unnoticed with minor buccal ulceration observed on a few occasions whereas in cynomolgus, primary infection has not been reported as obviously sym ptomatic . In both species the infection subsequently becomes latent in trigeminal ganglia, with or without infection of other sensory ganglia. Reactivation results in virus shedding without any further clinical signs.
Transmission within a monkey colony is by direct contact, bites, scratches, possibly venereally and by contamination of food and water by saliva. Infection does not appear to be transmitted vertically and anim als appear to seroconvert around puberty (Zwart ouw e t a l. 1984). Prevalence of antibodies varies from about 11% at one year old to 97% at 2.5 years old (Pille 1960 , Weigler e t a l. 1990 ). It remains unresolved whether infection is sexually transmitted, or is spread to other animals exclusively by bit es or abrasions contaminated with saliva and by aerosols entering through the conjunctiva, nose or pharynx. All but one of the documented infections of man have occurred by bite or direct contact with macaque tissues or bodȳ uids. T he exception is one case of humanto-human transmission (Weigler 1992) .
BV has been shown to be highly pathogenic in non-macaque primat e species. Indeed, there have been about 40 human cases reported with a fatalit y rate in excess of 70% (Holm es e t a l. 1995 ), alm ost all resulting from occupational exposure. For this reason the establishment of SPF macaque colonies is actively pursued (Ward & Hilliard 1994 , Hilliard & Ward 1999 .
T his paper describes the results of a BV testing programme with the aim of establishing a BV SPF colony from a group of macaques in which BV was an indigenous pathogen and gives details of some anomalous results from immunosuppressed anim als, that support results from a previous study.
Materials and methods
All the animals were kept in accordance with the UK Home Of®ce Code of Practice for the Housing and Care of Animals used in Scienti®c Procedures under the Animals (Scienti®c Procedures) Act 1986. All the anim als were housed indoors at 15±24 C with 10±12 air changes per hour and a 12:12 light=dark cycle.
During the course of BV investigat ions and while waiting for test results, the personnel involved with the care of the anim als were advised that the animals should be handled only when wearing protective clothing including safety goggles, gloves and a mask. T he animals were cage-rested at the tim e of sampling and no longer on dai ly testing procedures. Under no circumstances was either perfusion or any neurosurgery permitted. All cleaning out in the animal holding room was done wearing full protective clothing, again including goggles, gloves and mask.
BV se ro lo gica l a ssa ys
Primary screening for BV antibodies was undertaken by competitive radio-im munoassay (com pria). Brie¯y, sera were tested for the ability to compete with the binding of a BV-positive reference serum on a BV-infected cell antigen (Norcott & Brown 1993 ) . 0±30% binding was interpreted as negative, 31±60% was equivocal and 61±100% was positive. Compria positivity was con®rmed by serum neutralization (SN ) of BV infectivity. T he serum neutralization test titres were determined by reacting serial diluti ons of sera with a constant tit re of BV, and adding this mixture to continuous monkey cell cultures (Vero) grown in microtitre plates. A positive serum inhibits (neutralizes) virus growth relat ive to a control inoculum. A serum is regarded as being seronegative if it fails to neutralize infectivity at a dilution of 1 in 2.
Ind ire ct im m uno¯uo re sc e nc e : BV-infected monkey kidney cells (Vero) were acetone ®xed, reacted with macaque sera and bound antibodies detected with goat anti-human IgG labelled with FIT C (DAKO). T he goat anti-human antibody is strongly reactive with macaque IgG. Positivity was assessed relative to uninfected Vero cells.
We ste rn b lo tting: Brie¯y, polypeptides from BV-infected Vero cells were separated on 12% polyacrylamide gels, electroblotted onto polyvinyl membranes, and reacted with macaque sera. Bound antibodies were detected with goat anti-human IgG labelled with horseradish peroxidase (DAKO) and ECL plus chemiluminescent detecting reagent (Amersham). Positivity was determined by the detection of reactivity relative to control blots of uninfected Vero cell proteins.
Results

B virus sc re e ning o f th e c o lo ny
In January 1992 there were 252 Old World primates in four different depart ments in the University, with no clear data on their BV serological status. All of the departments used the animals experimentally and one (departm ent B) included a breeding colony of rhesus monkeys. At this tim e a screening program me was introduced. One serum sample was taken from each anim al; those that were negative or equivocal on a compria test were sampled again aft er 2 months. T here were two negative results from each of 144 rhesus, 73 cynomolgus and 10 vervet monkeys. T he 25 (14 cynomolgus, 10 rhesus and 1 vervet) other animals (10% ) gave positive or equivocal results on one or both tests. T he equivocal compria tests were con®rmed as positive or negative by a serum neutralization (SN ) test. T here were a total of 20 con®rmed positive animals that were all culled, apart from one cynomolgus (Lennox) with a high equivocal compria result. T his anim al remained singly housed in department A until it was killed in December 1997, when its experimental programme was completed. T he ®ve other animals, that gave equivocal results on compria but negative results on SN, were con®rmed as negatives by Western blot test and ELISA.
All animals were screened from 1993 on an annual basis and all animals being brought into the University were sampled, initially, twice at two monthly intervals unless they originated from a colony with a welldocumented negative B virus history. From 1993 through to 1997, all the animals in the University gave negative results on this annual compria apart from Lennox and one rhesus breeding fem ale monkey (A20 ) in department B. A20 had an equivocal compria result in 1992, which was con®rmed negative by SN at that tim e. T he annual compria and SN results for A20 are shown in Table 1 . In 1997, in an attem pt to resolve the continuing BV equivocal stat us of this anim al, indirect immuno¯uorescence testing was undertaken against a range of simplex like herpesviruses (Table 2) . Results indicated the highest antibody titre against BV and thus it was concluded that the animal was B virus seropositive. T he anim al was culled.
Im m uno suppre sse d a nim a ls
In 1998 the annual screen of all the macaques in the University gave negative results, but in 1999 one rhesus macaque (Daphne) in department A was positive on compria.
Daphne was born on 4 July 1995 in department B. Serum samples were tak en on 1 April 1996 and 4 Marc h 1997, both of which were negative on compria. Her clinical history was unremark able, her experimental history involved immunization with DNA and subsequent blood sampling in 1996, before transfer from departm ent B to department A in September 1997. A sample taken in August 1998 as part of the annual screening process was also negative on compria.
In Marc h 1999 as part of the experimental program me to which Daphne was assigned, neurosurgery was carried out to create a unilat eral left cholinergic basal forebrain lesion. In order to prevent postoperative cerebral oedema she was given a total of 35.2 mg dexamethasone (Decadron injection, MSD ) over the 3 days following surgery. In April 1999 a second operation was performed to create a lesion in the right tem poral lobe of the cortex. In June 1999 at the routine annual screen the serum gave a positive compria result.
Daphne was grouped housed with two other rhesus monkeys, Dulcy and Kahenata, so additional samples were taken from all three animals. Dulcy had also originated from departm ent B and had an experimental backgroun d in immunology, having received both DNA and modi®ed vaccinia vaccines in 1996 =7. She had been transferred to she underwent neurosurgery, also to create a unilateral cholinergic lesion, which resulted in severe cerebral oedema for which she received 84 mg dexamethasone between days 4 and 9 postoperatively and 25 mg methylprednisolone on day 7. Both Kahenata and Dulcy gave equivocal results on compria in July 1999, whereas the samples tak en just 3 months earlier at the annual screen in April 1999, before the immunosuppressive therapy, had been negative (Table 3) . Repeated compria tests on Daphne continued to be positive and on Kahenata and Dulcy continued to be equivocal (Table 3) . However both SN and Western blot failed to con®rm the compria results. Indirect im munouorescence on the initial serum samples from Dulcy demonstrated a high level of non-speci®c reactivity. In particular, the serum contained high levels of cells of a macro-phage=®broblast appearance. Centrifugation at 13 000 g to remove this cellular in®ltrate did not alter the results obtained in any assay with this serum. Overall, it was not possible to con®rm the positive and equivocal results in the BV compria by either Western blotting or virus neutralization. Given the previous BV negative history of these anim als, these results were interpreted as false positive reactivity, possibly resulting from the im munosuppressive regim en.
Discussion
In view of the high pathogenicity of BV in non-macaque primates, the Advisory Committee on Dangerous Pathogens has recently reclassi®ed BV into hazard group 4 (ACDP 1998 ). In the event of an animal being diagnosed as seropositive it strongly advises that such an animal be destroyed and incinerated. If this is not done then the animal should be handled at full animal containment level 4, which would have im plications for the animal's welfare requirements.
T he guidelines also advise that negative results from sexually immature macaques should be regarded with caution as lat ent infection may be present and may be reactivated by stress or im munosuppression. It recommends that a representative sample of Old World monkeys held long term in any RIAˆradioimmunoassay g facility should be tested annually and in the event of a seropositive animal being found, the rest of the colony should be tested and the appropriat e action taken. T his report provides support for such regular testing programmes and has highlighted problems in interpreting BV serological tests from immunosuppressed macaques. False seropositivity to BV in immunosuppressed macaques has been docum ented previously. In a study of renal allograft tolerance using 102 rhesus macaques, two seroconverted to BV, six seroreverted from BV seropositive to seronegative and a further two seroconverted and then reverted to their original seronegative stat us (Olson e t a l. 1991 ). Animals were immunosuppressed using various methodologies including antithymocyte globulin, cyclosporin A or total lym phoid irradiation (T LI) with or without splenectom y. All the animals from which inconsistent serological results were obtained had been suppressed by T LI. BV testing was by an indirect dot-immunobinding assay (Heberling & Kalter 1987) , a quite distinct methodology from the competitive radioimmunoassay used for the testing in this report. Together the results in this and the previous report suggest that immunosuppression of rhesus macaques by different methods, T LI or glucocorticoids, can result in a false seropositivity to BV antigens. As to why immunosuppression should lead to false positivity is unclear. T he im mune suppression regimens used in both studies would be anticipated to impair B cell response, giving false negative results, seroreversion not seropositivity (Zan-Bar 1984 , Miller 1997 . Clearly further studies are required to explain these odd results. Overall, the failure to con®rm BV seropositivity in extended serological tests, in addition to the fact that there was no evidence of transmission of undetected BV to other members of the colony, validates the conclusion of fal se BV seropositivity.
Precise stim uli for BV reactivation and transmission remain to be de®ned; however, as with HSV, immunosuppression is an effective stimulus (Chellman e t a l. 1992 ) . In one study a single anim al in a group of six fem ale monkeys given an immunosuppres-sive agent excreted virus from both the vagina and the mouth (Zwartouw & Boulter 1984 ) . It may appear that BV was relatively resistant to reactivation in the other ®ve animals, however sensitivity of detection of shed virus should be considered. A number of studies have described a low frequency of BV isolation from seropositive macaques, however, it remains unclear if this low isolation rate re¯ects infrequent shedding or technical dif®culties in primary culture of BV. Recent studies of experimental infections have demonstrated that virus shedding can be detected by polymerase chain reaction (PCR) when virus isolation by traditional methods has been unsuccessful (Slom ka e t a l. 1997 ). T hese dat a and colony seroepidemiological studies would support very frequent shedding of BV from infected macaques.
T he incidence of BV infection, as estim ated by isolations from genital tissues and associat ed ganglia, appears highest around puberty, leading some researchers to conclude that the transmission is venereal (Zwartouw e t a l. 1984 ) . However this conclusion may be confounded by the possible risk fact ors that occur routinely in conjunction with breeding act ivity such as grooming and aggression. In one 16-m onth study of 157 animals (Weigler e t a l. 1993 ), the data indicated that cage mat e aggression was the primary risk fact or for BV infection. T hose monkeys that were bitten and scratched were nearly ®ve times more likely to become infected during the same tim e period than monkeys that were not attac ked. Male and fem ale monkeys were at equal risk of infection in group-housed facilities and social dominance rank did not predict risk of BV infection. A recent PCR-based study of a rhesus macaque colony that examined the ganglionic sites of BV latency, concluded that whilst sexual contact was signi®cant it was not the predominant mode of transmission between monkeys (Weigler e t a l. 1995 ).
Overall, the data suggest that although experimental' immunosuppression may lead to BV reactivation and shedding,`normal' stimuli within the colony will result in frequent reactivat ion and transmission of infection. A serological screening programme will therefore rapidly detect the presence of BV-infected anim als within a colony. If, as in this colony, the antibody stat us of macaques is monitored regularly, breeding colonies, free of BV, can be established. In this case the criterion for seronegative status was that each animal had a negative test for BV antibody on two occasions separated by at least 2 months, during which it was isolated from other monkeys that might have been carrying the virus. Such a seronegative anim al has a very low probability of carrying latent BV infection; however, given the history of the colony, an ongoing screening program me was establ ished.
T he comprehensive programme of testing that had been established in the source colony and the experimental facility over previous years, enabled us to interpret the initial positive (non-negati ve) result from an immunosuppressed animal, Daphne, with some caution, and allowed tim e for further testing. T his incident indicates the importance of a comprehensive BV serological testing programme in a research facil ity and of a good relati onship with the source colony that can provide full bac kground data. Evidently, the high doses of steroid these anim als received affec ted the serum in some way that interferes with the compria test. T he basis for this interference remains unclear. T he con®rmat ory assays of SN and Western blot were not subject to this interference. Overall, these results stress the importance of interpreting BV serological testing in the context of full clinical informat ion such that rare confounding fact ors are properly recognized in diagnosis.
